Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPreferred Stock LiabilitiesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Rhythm Pharmaceuticals (RYTM) Retained Earnings (2016 - 2025)

Rhythm Pharmaceuticals (RYTM) has disclosed Retained Earnings for 10 consecutive years, with -$1.4 billion as the latest value for Q4 2025.

  • On a quarterly basis, Retained Earnings fell 3589643.59% to -$1.4 billion in Q4 2025 year-over-year; TTM through Dec 2025 was -$1.4 billion, a 3589643.59% decrease, with the full-year FY2025 number at -$1.4 billion, down 3589643.59% from a year prior.
  • Retained Earnings was -$1.4 billion for Q4 2025 at Rhythm Pharmaceuticals, down from -$1.3 billion in the prior quarter.
  • In the past five years, Retained Earnings ranged from a high of -$6000.0 in Q1 2023 to a low of -$1.4 billion in Q4 2025.
  • A 5-year average of -$480.2 million and a median of -$507.5 million in 2021 define the central range for Retained Earnings.
  • Peak YoY movement for Retained Earnings: skyrocketed 100.0% in 2023, then tumbled 3589643.59% in 2025.
  • Rhythm Pharmaceuticals' Retained Earnings stood at -$528.9 million in 2021, then plummeted by 34.24% to -$710.1 million in 2022, then decreased by 26.01% to -$894.7 million in 2023, then skyrocketed by 100.0% to -$39000.0 in 2024, then crashed by 3589643.59% to -$1.4 billion in 2025.
  • Per Business Quant, the three most recent readings for RYTM's Retained Earnings are -$1.4 billion (Q4 2025), -$1.3 billion (Q3 2025), and -$2.2 million (Q2 2025).